• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Genomics >Candidate tumor suppressor genes at FRA7G are coamplified with MET and do not suppress malignancy in a gastric cancer.
【24h】

Candidate tumor suppressor genes at FRA7G are coamplified with MET and do not suppress malignancy in a gastric cancer.

机译：FRA7G的候选肿瘤抑制基因与MET共同扩增，不抑制胃癌的恶性肿瘤。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Common fragile sites predispose to specific chromosomal breakage associated with deletion, amplification, and/or translocation in certain forms of cancer. Chromosomal fragile sites not only are susceptible to DNA instability in cancer cells, but may also be associated with genes that contribute to the neoplastic process. FRA7G is a common fragile site containing the candidate tumor suppressor genes CAV1, CAV2, and TESTIN (TES). The human gastric cancer cell line GTL-16 has an amplification of this genomic region and was used to seek evidence for the suppressor candidacy of one of these genes. Our results demonstrate that CAV1, CAV2, and TESTIN are coamplified with the MET oncogene and overexpressed in GTL-16. Somatic mutation was not detected in the coding regions of these genes, although they were each overexpressed. The results show that CAV1, CAV2, and TESTIN are not tumor suppressor genes in this gastric cancer.
机译：常见的易碎位点易导致与某些形式的癌症中的缺失，扩增和/或易位相关的特定染色体断裂。染色体易碎位点不仅易受癌细胞中DNA不稳定的影响，而且还可能与有助于肿瘤形成过程的基因有关。 FRA7G是一个常见的易碎位点，其中包含候选肿瘤抑制基因CAV1，CAV2和TESTIN（TES）。人胃癌细胞系GTL-16具有该基因组区域的扩增，并用于寻找这些基因之一的抑制候选资格的证据。我们的结果表明，CAV1，CAV2和TESTIN与MET癌基因共同扩增，并在GTL-16中过表达。尽管这些基因均过表达，但在这些基因的编码区未检测到体细胞突变。结果表明，CAV1，CAV2和TESTIN不是该胃癌的抑癌基因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号